

た場面においても、このような肥満と癌の関連を強調することは少ない。肥満、糖尿病と癌について多くの研究結果が報告されており、複数の癌との関連が確定的になっている現状から、癌の一次予防としての肥満について、今よりも広く情報提供していく必要があるだろう。また、肥満や糖尿病が大腸がんの危険因子であるならば、健康診断などの二次予防の分野でも有効利用できる可能性がある。例えば、便潜血検査は非侵襲的、簡便、安価であり、大腸がんのスクリーニングとして確立されているが、一方、早期がんの場合しばしば陰性となる。大腸がんが増加している現状をふまえると、便潜血陽性者以外にも、内臓脂肪蓄積、糖尿病、家族歴等の情報を用いた何らかの方法でハイリスクグループを特定し、数年間隔で大腸精密検査を推奨することも有用かもしれない。今後、このような分野の発展にも期待したいところである。

■文 献

- 1) Calle EE, Rodriguez C, Walker-Thurmond K, *et al*. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. *N Engl J Med*. **348** : 1625-38, 2003.
- 2) American Institute for Cancer Research (AICR). New estimate : excess body fat alone causes over 100,000 cancers in US each year. Researchers present data linking obesity/overweight to higher cancer risk, poorer cancer survival. Available at : http://www.aicr.org/site/News2/1028460841?abbr=pr_ & page=NewsArticle & id=17333 & news_iv_ctrl=1102. Accessed November 9, 2009
- 3) Vigneri P, Frasca F, Sciacca L, *et al*. Diabetes and cancer. *Endocr Relat Cancer*. **16** : 1103-23, 2009.
- 4) Giovannucci E, Harlan DM, Archer MC, *et al*. Diabetes and cancer : a consensus report. *Diabetes Care*. **33** : 1674-85, 2010.
- 5) Inoue M, Iwasaki M, Otani T, *et al*. Diabetes mellitus and the risk of cancer : results from a large-scale population-based cohort study in Japan. *Arch Intern Med*. **166** : 1871-7, 2006.
- 6) Yamamoto S, Nakagawa T, Matsushita Y, *et al*. Visceral fat area and markers of insulin resistance in relation to colorectal neoplasia. *Diabetes Care*. **33** : 184-9, 2010.
- 7) Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect : the metabolic requirements of cell proliferation. *Science*. **324** : 1029-33, 2009.
- 8) World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer : a Global Perspective. AICR, Washington DC (2007)
- 9) Otake S, Takeda H, Suzuki Y, *et al*. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma : evidence for participation of insulin resistance. *Clin Cancer Res*. **11** : 3642-6, 2005.
- 10) Kang HW, Kim D, Kim HJ, *et al*. Visceral obesity and insulin resistance as risk factors for colorectal adenoma : a cross-sectional, case-control study. *Am J Gastroenterol*. **105** : 178-87, 2010.
- 11) Sass DA, Schoen RE, Weissfeld JL. Relationship of visceral adipose tissue to recurrence of adenomatous polyps. *Am J Gastroenterol*. **99** : 687-93, 2004.
- 12) Tabuchi M, Kitayama J, Nagawa H. Hyperglycemia and hypertriglyceridemia may associate with the adenoma-carcinoma transition in colorectal epithelial cells. *J Gastroenterol Hepatol*. **23** : 985-7, 2008.
- 13) Chung YW, Han DS, Park YK, *et al*. Association of obesity, serum glucose and lipids with the risk of advanced colorectal adenoma and cancer : a case-control study in Korea. *Dig Liver Dis*. **38** : 668-72, 2006.
- 14) Erarslan E, Turkay C, Koktener A, *et al*. Association of visceral fat accumulation and adiponectin levels with colorectal neoplasia. *Dig Dis Sci*. **54** : 862-8, 2009.
- 15) Schoen RE, Tangen CM, Kuller LH. Increased blood glucose and insulin, body size, and incident colorectal cancer. *J Natl Cancer Inst*. **91** : 1147-54, 1999.
- 16) Fischon T, Lahmann PH, Boeing H, *et al*. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). *J Natl Cancer Inst*. **98** : 920-31, 2006.
- 17) Stürmer T, Buring JE, Lee IM, *et al*. Metabolic abnormalities and risk for colorectal cancer in the physicians' health study. *Cancer Epidemiol Biomarkers Prev*. **15** : 2391-7, 2006.
- 18) Ma J, Giovannucci E, Pollak M, *et al*. A prospective study of plasma C-peptide and colorectal cancer risk in men. *J Natl Cancer Inst*. **96** : 546-553, 2004.

Effect of Longitudinal Changes in Visceral Fat Area and Other Anthropometric Indices to the Changes in Metabolic Risk Factors in Japanese Men

The Hitachi Health Study

YUMI MATSUSHITA, PHD¹
 TORU NAKAGAWA, MD, PHD²
 SHUICHIRO YAMAMOTO, MD, PHD²
 YOSHIHIKO TAKAHASHI, MD, PHD³

TETSUJI YOKOYAMA, MD, PHD⁴
 TETSUYA MIZOUE, MD, PHD⁵
 MITSUHIKO NODA, MD, PHD³

OBJECTIVE—The effects of longitudinal changes in the visceral fat area (VFA), and other anthropometric indices, on the risk factors of metabolic syndrome were not studied. We calculated the changes in metabolic risk factors in relation to changes in certain anthropometric indices in a large-scale study of Japanese men.

RESEARCH DESIGN AND METHODS—The subjects were 1,106 men participating in the Hitachi Health Study who received a computed tomography examination in both 2004 and 2007. VFA, subcutaneous fat area (SFA), and waist circumference were measured using the computed tomography. We examined how longitudinal changes in each anthropometric index over a 3-year period influenced the value of each metabolic risk factor.

RESULTS—Changes (Δ) over a 3-year period in body weight, SFA, and waist circumference strongly correlated, while the changes in body weight and VFA were weakly correlated. Changes in the VFA were associated with changes in metabolic risk factors, especially changes in triglyceride and HDL; we found these changes to be independent of the Δ body weight and Δ waist circumference.

CONCLUSIONS—Change in body weight is not a precise surrogate marker of Δ VFA, and repeated VFA measurements over time are useful. Adopting a lifestyle that does not increase the VFA is important in preventing metabolic syndrome.

Cardiovascular disease (CVD) is one of the leading causes of morbidity and mortality in the world (1). Previous reports have shown that obesity plays a significant role in increasing cardiovascular risk (2). Certain indicators of obesity, such as the visceral fat area (VFA), or visceral adipose tissue, are more strongly associated with the risk of CVD than other indicators of obesity,

such as waist circumference, BMI (3), or the subcutaneous fat area (SFA) (2). A large VFA is strongly related to a higher prevalence of impaired fasting glucose levels (4,5), diabetes (4,6,7), insulin resistance (4,8–10), hypertension (11,12), abnormality of lipid metabolism (13–16), and metabolic risk factors (14,17,18). Previous studies have examined the relationship between baseline VFA and

metabolic risk factors. In a previous intervention study of 54 postmenopausal women, an increase in VFA strongly correlated with changes in triglyceride and HDL cholesterol levels compared with changes in the blood pressure and fasting blood glucose levels (19). In the current study, we examined the relationships between changes in the VFA, SFA, body weight, and waist circumference and changes in CVD risk factors to determine the relative contributions of the longitudinal changes in these anthropometric indices to the changes in metabolic risk factors over a 3-year period. Determining the relationships between the anthropometric indices and metabolic risk factors would be useful for preventing CVD in clinical settings.

RESEARCH DESIGN AND METHODS

Overall, a total of 13,971 male employees and their spouses, after ≥ 12 h of fasting, underwent health check-ups during a baseline survey performed in 2004 and 2005 at the Hitachi Health Care Center in Ibaraki Prefecture. Of these, 2,655 men received a computed tomography scan. The final analysis involved 1,106 men from the initial study who participated in a 3-year follow-up survey performed in 2007 and 2008 (aged 30–72 years in the baseline survey). The mean age of the men for whom follow-up data were available was younger than that of the men for whom follow-up data were not available. In addition, the mean age of the men who received a computed tomography examination in the baseline survey was greater than the mean age of the men who did not receive the computed tomography examination. No significant differences were seen between the other characteristics when age-adjusted comparisons were performed. Self-reporting questionnaires were used to investigate whether the subjects were currently receiving medical treatment for hyperlipidemia, hypertension, or diabetes

From the ¹Department of Clinical Research Coordination, National Center for Global Health and Medicine, Tokyo, Japan; ²Hitachi Health Care Center, Hitachi, Ltd., Ibaraki, Japan; the ³Department of Diabetes and Metabolic Medicine and Diabetes Research Center, National Center for Global Health and Medicine, Tokyo, Japan; the ⁴Department of Health Promotion, National Institute of Public Health, Saitama, Japan; and the ⁵Department of Epidemiology and Prevention, National Center for Global Health and Medicine, Tokyo, Japan.

Corresponding author: Yumi Matsushita, ymatsushita@ri.ncgm.go.jp.

Received 14 July 2011 and accepted 19 January 2012.

DOI: 10.2337/dc11-1320

© 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

Changes in VFA and incidence of CVD risk

at the time of both surveys. Body height and weight were measured using an automated scale (BF-220; Tanita), and the BMI was defined as the weight in kilograms divided by the square of the height in meters. VFA, SFA, and waist circumference were measured using a computed tomography scanner and protocols previously described (20). In brief, single-slice imaging was performed at the umbilical level in a spine position using a Redix turbo CT machine (Hitachi Medico). The imaging conditions were 120 kV, 50 mA, and a slice thickness of 5 mm. VFA, SFA, and waist circumference were calculated using fatPointer software (Hitachi Medico). Triglyceride and HDL cholesterol levels were measured using the oxygen method with a Hitachi 7600 device (Sekisui Medical). Blood glucose levels were measured using the glucose electrode technique with an ADAMS glucose GA-1170 device (Arkrey). Blood pressure was measured using an oscillometric method with a Kentaro ADVANCE BP-203RV III A/B device (Colin) while the patient was in a sitting position and after the patient had rested for 3 min. Informed consent was obtained from each examinee regarding the use of his or her data for research purposes. The current study was approved by the ethics review committee of the National Center for Global Health and Medicine.

Definition of the state of risk factor clustering

Subjects with two or more of the following four factors, defined by the National Cholesterol Education Program's Adult Treatment Panel III guidelines (21), with the exception of waist circumference, were defined to have clustering of metabolic risk factors: 1) triglyceride ≥ 150

Table 1—Anthropometric and CVD risk variables at baseline and changes during the 3-year follow-up period (n = 1,106)

	Baseline		Changes in 3-year period		P*
	Mean	SD	Mean	SD	
Height (cm)	169.0	6.1	0.3	0.5	<0.001
Weight (kg)	67.6	9.4	0.0	3.1	0.61
BMI (kg/m ²)	23.6	2.7	0.1	1.1	0.018
VFA (cm ²)	120.0	52.2	0.0	32.5	0.99
SFA (cm ²)	122.6	52.2	4.2	24.7	<0.001
VFA/SFA	1.03	0.54	-0.03	0.48	0.055
WC (cm)	85.6	8.1	-0.2	4.6	0.088
SBP (mmHg)	121.5	11.7	-1.1	10.8	0.001
DBP (mmHg)	76.9	8.2	-0.1	7.1	0.62
TG (mg/dL)	137.6	92.6	-9.0	80.0	<0.001
HDL cholesterol (mg/dL)	56.4	14.2	-1.8	7.9	<0.001
Fasting glucose (mg/dL)	105.2	13.0	-1.5	8.7	<0.001

TG, triglyceride; WC, waist circumference. *Paired *t* test between values at baseline and at the 3-year follow-up.

mg/dL (1.69 mmol/L), 2) HDL cholesterol <40 mg/dL (1.03 mmol/L), 3) systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 85 mmHg, or 4) fasting plasma glucose ≥ 110 mg/dL (6.11 mmol/L). Subjects currently receiving treatment for hyperlipidemia, hypertension, or diabetes were deemed as having the respective risk factor, regardless of the biochemical value.

Statistical analyses

The baseline data and the 3-year changes (Δ) in CVD risk-related variables (i.e., BMI, VFA, SFA, VFA/SFA, waist circumference, SBP, DBP, triglyceride, HDL cholesterol, and glucose) were calculated for subjects who had not received a medical treatment in both surveys. The *P* value between baseline and the 3-year follow-up period was calculated using a paired

t test. Pearson correlation coefficients for the changes in the anthropometric and CVD risk variables were calculated. To establish the independent contribution of each anthropometric variable, multiple linear regression analyses were used to obtain the standardized partial regression coefficients, where the change in the CVD risk variable was the dependent variable and the changes in the anthropometric indices were the independent variables; a stepwise procedure was used to select significant variables. All analyses were performed using SPSS (version 15.0; SPSS, Chicago, IL).

RESULTS—The anthropometric and CVD risk variables at the baseline survey and changes at the 3-year follow-up period are shown in Table 1. The mean (SD) age of the subjects was 52.7 (8.4)

Table 2—Pearson correlations coefficients among changes in anthropometric and CVD risk variables (n = 1,106)

	Δ VFA	Δ SFA	Δ Body weight	Δ Waist circumference	Δ BMI	Δ SBP	Δ DBP	Δ Fasting glucose	Δ Log triglycerides	Δ HDL
Δ VFA	1	0.632	0.672	0.756	0.671	0.138	0.162	0.188	0.197	-0.234
Δ SFA	0.632	1	0.738	0.765	0.738	0.174	0.177	0.187	0.171	-0.238
Δ Body weight	0.672	0.738	1	0.722	0.989	0.155	0.210	0.203	0.222	-0.252
Δ Waist circumference	0.756	0.765	0.722	1	0.718	0.140	0.156	0.168	0.196	-0.233
Δ BMI	0.671	0.738	0.989	0.718	1	0.150	0.203	0.204	0.225	-0.253
Δ SBP	0.138	0.174	0.155	0.140	0.150	1	0.627	0.055	0.096	-0.003
Δ DBP	0.162	0.177	0.210	0.156	0.203	0.627	1	0.093	0.097	-0.004
Δ Fasting glucose	0.188	0.187	0.203	0.168	0.204	0.055	0.093	1	0.039	0.041
Δ Log triglycerides	0.288	0.280	0.350	0.295	0.353	0.109	0.117	0.079	1	-0.288
Δ HDL cholesterol	-0.234	-0.238	-0.252	-0.233	-0.253	-0.003	-0.004	0.041	-0.250	1

The absolute value of a correlation coefficient >0.06 was statistically significant at *P* < 0.05. The correlation coefficients were essentially unchanged after adjustments for age (data not shown).

years at baseline. The mean BMI was 23.6 (2.7) kg/m², the mean VFA was 120.0 (52.2) cm², and the mean waist circumference was 85.6 (8.1) cm at baseline. The 3-year changes in each of these parameters were relatively small.

Pearson correlation coefficients for the changes in the anthropometric measurements and CVD risk variables are shown in Table 2. Strong correlations among the changes in the four adiposity indices were observed, with a colinearity observed among the indices. Correlations among the Δ body weight, Δ SFA, and Δ waist circumference were also strong, but the correlation between the Δ body weight and Δ VFA was weak. These findings suggested that the Δ body weight was not an exact surrogate marker of Δ VFA. We also analyzed correlations among the changes in anthropometric measurements and CVD risk variables. Significant correlations between the Δ log triglyceride and Δ VFA, the Δ log triglyceride and Δ body weight, the Δ SBP and Δ SFA, the Δ SBP and Δ body weight, and the Δ glucose and Δ body weight were observed. The correlation coefficients were essentially unchanged after adjustments for age (data not shown).

Multiple linear regression analyses showed that the changes in VFA, SFA, body weight, and waist circumference were independently associated with the changes in CVD risk factors during the 3-year follow-up period (Table 3). The Δ DBP, Δ glucose, Δ log triglyceride, and Δ HDL cholesterol were significantly affected by both the Δ VFA and Δ SFA. In contrast, the Δ SBP was only significantly affected by the Δ SFA. The Δ log triglyceride and Δ HDL cholesterol values were more strongly affected by the Δ VFA than by the Δ SFA. These results suggest that the Δ VFA and Δ SFA contribute differently to the Δ CVD risk variables. A multiple regression analysis showed that the Δ VFA were significantly related to the Δ log triglyceride and Δ HDL cholesterol and were independent of the Δ body weight and Δ waist circumference.

CONCLUSIONS—This study investigated the change in metabolic risk factors between a baseline examination and a 3-year follow-up examination, measured using computed tomography. The changes in body weight, SFA, and waist circumference strongly correlated. The changes in body weight and VFA showed weak correlation, suggesting that changes in body weight are not an exact surrogate marker

Table 3—Independent associations of changes in VFA, SFA, body weight, and waist circumference with changes in the CVD risk factors during the 3-year follow-up period according to multiple linear regression analyses

Dependent variable	Independent variables	Model 1		Model 2	
		Standardized partial β	P	Standardized partial β	P
Δ SBP	Δ VFA	0.056	0.115	—	—
	Δ SFA	0.161	<0.001	0.194	<0.001
Δ DBP	Age	0.034	0.216	—	—
	Δ VFA	0.093	0.008	0.093	0.008
	Δ SFA	0.135	<0.001	0.135	<0.001
Δ Fasting glucose	Age	-0.105	<0.001	-0.105	<0.001
	Δ VFA	0.100	0.002	0.100	0.002
	Δ SFA	0.127	<0.001	0.127	<0.001
Δ Log triglycerides	Age	-0.071	0.005	-0.071	0.005
	Δ VFA	0.207	<0.001	0.206	<0.001
	Δ SFA	0.141	<0.001	0.143	<0.001
Δ HDL cholesterol	Age	-0.026	0.295	—	—
	Δ VFA	-0.154	<0.001	-0.154	<0.001
	Δ SFA	-0.134	<0.001	-0.134	<0.001
Δ SBP	Age	-0.082	0.001	0.082	0.001
	Δ VFA	0.031	0.480	—	—
	Δ SFA	0.121	0.011	0.128	0.002
	Δ Body weight	0.084	0.067	0.089	0.031
	Δ Waist	-0.009	0.866	—	—
Δ DBP	Age	0.041	0.142	—	—
	Δ VFA	0.055	0.203	—	—
	Δ SFA	0.070	0.139	—	—
	Δ Body weight	0.157	0.001	0.220	<0.001
	Δ Waist	-0.035	0.507	—	—
Δ Fasting glucose	Age	-0.092	0.001	-0.088	0.001
	Δ VFA	0.080	0.040	—	—
	Δ SFA	0.085	0.045	—	—
	Δ Body weight	0.158	<0.001	0.223	<0.001
	Δ Waist	-0.082	0.070	—	—
Δ Log triglycerides	Age	-0.053	0.037	—	—
	Δ VFA	0.112	0.003	0.127	<0.001
	Δ SFA	0.008	0.846	—	—
	Δ Body weight	0.229	0.000	0.248	<0.001
	Δ Waist	0.031	0.483	—	—
Δ HDL cholesterol	Age	-0.006	0.813	—	—
	Δ VFA	-0.105	0.004	-0.112	0.001
	Δ SFA	-0.065	0.106	-0.073	0.043
	Δ Body weight	-0.116	0.003	—	—
	Δ Waist	-0.017	0.684	-0.119	0.002
	Age	-0.092	<0.001	-0.093	<0.001

Model 1: All independent variables were entered into the model. Model 2: Significant variables were selected using the stepwise method. β , regression coefficient

of changes in VFA. A multiple regression analysis showed that the Δ VFA was significantly related to Δ triglyceride and Δ HDL cholesterol independently of Δ body weight and Δ waist circumference, suggesting the importance of monitoring VFA over time.

In previous cross-sectional studies, positive correlations between VFA and SBP and between VFA and serum triglyceride

were reported to be significant when VFA was measured by computed tomography (14). In previous longitudinal studies, the effects of changes in BMI (22), weight (23), and waist circumference (24,25) on metabolic risk factors were examined. One such report showed a strong linear trend between increasing BMI and a worsening of various variables of metabolic risk factors, including blood pressure and lipid

profiles (24). Likewise, another report showed that weight changes were linearly related to all measurements of each component of the metabolic risk factors (23). Other studies have shown that a reduction in the waist circumference and the VFA achieved through lifestyle modifications is closely linked to an improvement in metabolic risk factors (19,25). These studies suggest that the changes in BMI, weight, waist circumference, and VFA are related to risk factors for CVD. However, the impact of the change in the VFA (measured twice in the same person), which is regarded as the strongest indicator of CVD risk among the anthropometric variables, has remained uncertain. To our knowledge, this is the first study to analyze the relationships between changes in VFA and changes in metabolic risk factors, compared with other anthropometric variables, in a large population. Our findings clearly showed that the Δ VFA were significantly related to the Δ log triglyceride and Δ HDL cholesterol and were independent of the Δ body weight and Δ waist circumference.

In previous studies (22), the mean value of each component of metabolic risk factors or the prevalence of metabolic risk factors and its components were compared according to changes in BMI, body weight, and waist circumference. This is the first study that compared the strength of the association of metabolic risk factors with the change in VFA in a large population.

The current study has the following strengths: the study had a longitudinal design and examined the relationships between metabolic risk factors and the change in VFA using computed tomography scans performed twice on the same subject. The number of subjects was relatively large, with >1,000 subjects being followed over a 3-year period. Our study is thought to have a small measurement bias because VFA and SFA were measured using the same computed tomography machine, in the same region, and at the same state of expiration during both the baseline examination and the 3-year follow-up examination. A random measurement error could have diluted the relationship between Δ VFA and the metabolic risk factors. Thus, the real relationship may be stronger than the observed one. Nevertheless, the current study also has a limitation. The study subjects were limited to men, and further studies in women are needed.

In conclusion, the current study of Japanese men showed that changes in the

VFA were associated with changes in metabolic risk factors. The Δ VFA was significantly related to Δ log triglyceride and Δ HDL cholesterol and was independent of Δ body weight and Δ waist circumference, suggesting the importance of measuring the VFA repeatedly over time. The adoption of a lifestyle that does not result in an increase in VFA is important in preventing metabolic syndrome.

Acknowledgments—This study was supported by a grant from the Ministry of Health, Labour and Welfare of Japan.

No potential conflicts of interest related to this article were reported.

Y.M. was the principal investigator, researched data, contributed to discussions, wrote the manuscript, and reviewed and edited the manuscript. T.N. researched data, contributed to discussions, and reviewed and edited the manuscript. S.Y. researched data and reviewed and edited the manuscript. Y.T. contributed to discussions. T.Y., T.M., and M.N. contributed to discussions and reviewed and edited the manuscript. Y.M. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References

1. Ignarro LJ, Balestrieri ML, Napoli C. Nutritional, physical activity, and cardiovascular disease: an update. *Cardiovasc Res* 2007;73:326–340
2. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. *Circulation* 2007;116:39–48
3. Miyawaki T, Abe M, Yahata K, Kajiyama N, Katsuma H, Saito N. Contribution of visceral fat accumulation to the risk factors for atherosclerosis in non-obese Japanese. *Intern Med* 2004;43:1138–1144
4. Goodpaster BH, Krishnaswami S, Resnick H, et al. Association between regional adipose tissue distribution and both type 2 diabetes and impaired glucose tolerance in elderly men and women. *Diabetes Care* 2003;26:372–379
5. Hayashi T, Boyko EJ, Leonetti DL, et al. Visceral adiposity and the risk of impaired glucose tolerance: a prospective study among Japanese Americans. *Diabetes Care* 2003;26:650–655
6. Kanaya AM, Harris T, Goodpaster BH, Tykavsky F, Cummings SR; Health, Aging, and Body Composition (ABC) Study. Adipocytokines attenuate the association between visceral adiposity and diabetes in older adults. *Diabetes Care* 2004;27:1375–1380
7. Boyko EJ, Fujimoto WY, Leonetti DL, Newell-Morris L. Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. *Diabetes Care* 2000;23:465–471
8. Tulloch-Reid MK, Hanson RL, Sebring NG, et al. Both subcutaneous and visceral adipose tissue correlate highly with insulin resistance in African Americans. *Obes Res* 2004;12:1352–1359
9. Wagenknecht LE, Langefeld CD, Scherzinger AL, et al. Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. *Diabetes* 2003;52:2490–2496
10. Hayashi T, Boyko EJ, McNeely MJ, Leonetti DL, Kahn SE, Fujimoto WY. Visceral adiposity, not abdominal subcutaneous fat area, is associated with an increase in future insulin resistance in Japanese Americans. *Diabetes* 2008;57:1269–1275
11. Hayashi T, Boyko EJ, Leonetti DL, et al. Visceral adiposity is an independent predictor of incident hypertension in Japanese Americans. *Ann Intern Med* 2004;140:992–1000
12. Ding J, Visser M, Kritchevsky SB, et al. The association of regional fat depots with hypertension in older persons of white and African American ethnicity. *Am J Hypertens* 2004;17:971–976
13. Pascot A, Lemieux S, Lemieux I, et al. Age-related increase in visceral adipose tissue and body fat and the metabolic risk profile of premenopausal women. *Diabetes Care* 1999;22:1471–1478
14. Nagaretani H, Nakamura T, Funahashi T, et al. Visceral fat is a major contributor for multiple risk factor clustering in Japanese men with impaired glucose tolerance. *Diabetes Care* 2001;24:2127–2133
15. Nicklas BJ, Penninx BW, Ryan AS, Berman DM, Lynch NA, Dennis KE. Visceral adipose tissue cutoffs associated with metabolic risk factors for coronary heart disease in women. *Diabetes Care* 2003;26:1413–1420
16. Lemieux S, Prud'homme D, Moorjani S, et al. Do elevated levels of abdominal visceral adipose tissue contribute to age-related differences in plasma lipoprotein concentrations in men? *Atherosclerosis* 1995;118:155–164
17. Mori Y, Hoshino K, Yokota K, Yokose T, Tajima N. Increased visceral fat and impaired glucose tolerance predict the increased risk of metabolic syndrome in Japanese middle-aged men. *Exp Clin Endocrinol Diabetes* 2005;113:334–339
18. Carr DB, Utschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. *Diabetes* 2004;53:2087–2094
19. Matsuo T, Kato Y, Murotake Y, Kim MK, Unno H, Tanaka K. An increase in

- high-density lipoprotein cholesterol after weight loss intervention is associated with long-term maintenance of reduced visceral abdominal fat. *Int J Obes (Lond)* 2010;34:1742–1751
20. Nakagawa T, Yamamoto S, Irokawa M. Development of the Automated Diagnosis CT Screening System for Visceral Obesity. *Asian Pacific Journal of Disease Management*. 2008;2:31–38
21. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 2001; 285:2486–2497
22. Berrahmoune H, Herbeth B, Samara A, Marteau JB, Siest G, Visvikis-Siest S. Five-year alterations in BMI are associated with clustering of changes in cardiovascular risk factors in a gender-dependant way: the Stanislas study. *Int J Obes (Lond)* 2008;32:1279–1288
23. Hillier TA, Fagot-Campagna A, Eschwège E, Vol S, Cailleau M, Balkau B; D.E.S.I.R. Study Group. Weight change and changes in the metabolic syndrome as the French population moves towards overweight: the D.E.S.I.R. cohort. *Int J Epidemiol* 2006;35:190–196
24. Miyatake N, Matsumoto S, Fujii M, Numata T. Reducing waist circumference by at least 3 cm is recommended for improving metabolic syndrome in obese Japanese men. *Diabetes Res Clin Pract* 2008;79:191–195
25. Villareal DT, Miller BV 3rd, Banks M, Fontana L, Sinacore DR, Klein S. Effect of lifestyle intervention on metabolic coronary heart disease risk factors in obese older adults. *Am J Clin Nutr* 2006;84:1317–1323

Matsushita Y, Nakagawa T, Yamamoto S, et al:
Visceral Fat Area Cutoff for the Detection of Multiple Risk Factors of Metabolic Syndrome in Japanese : The Hitachi Health Study Obesity [Article first published online : 13 October 2011]
 DOI : 10.1038/oby.2011.285

成因

メタボリックシンドロームのリスク重積

2005年4月にメタボリックシンドロームの日本の診断基準が発表された。その基準を参考にして算出されたメタボリックシンドロームが強く疑われる者および予備群は、約1,960万人にも達するという。この診断基準の特徴は、内臓脂肪の蓄積の基準を最上位においたことである。しかし、内臓脂肪面積のカットオフ値が年齢別に異なるかは検討されていない。そこで、内臓脂肪面積のカットオフ値を性・年齢別に算出し、性・年齢別に異なる値が必要かどうかを明らかにすることを目的として本研究を行った。

2004年から2009年にかけて日立健康管理センタにて腹部CT検査(臍部normal slice)を行った11,561名を対象に、CTによる内臓脂肪面積の、メタボリックシンドロームのリスク重積を見出すための最適カットオフ値を、性・年齢別にROC解析により検討した。

解析対象者の平均年齢(標準偏差)は男性51.9(10.4)歳、女性55.8(9.8)歳であった。感度80%でメタボリックシンドロームのリスク重積者を拾い上げることのできる内臓脂肪面積は、40歳未満の若年層では小さく(40歳未満 vs. 40歳以上; 男性86.4cm² vs. 103.9cm², 女性36.5cm² vs. 69.2cm²)、また、ROC曲線の曲線下面積は男性に比べ女性で大きくなっており、いずれも年齢と共に小さくなる傾向が有意に認められた(男性; trend P=0.056, 女性; trend P=0.020)。

以上が表題文献の内容であり、性・年齢別に異なる内臓脂肪面積のカットオフ値が実際には必要であることを明らかにしたものである(表)。すなわち、全体で感度が80%と

表. 内臓脂肪面積とメタボリックシンドロームのリスク集積との関係
 男性

内臓脂肪面積	感度80%の値	感度80%の特異度	感度+特異度が最大の値	感度	特異度
40歳未満	86.4cm ²	49.2%	114.0cm ²	64.2%	72.9%
40代	103.6cm ²	52.6%	106.6cm ²	78.2%	55.4%
50代	104.5cm ²	47.3%	124.8cm ²	67.6%	62.6%
60代	102.1cm ²	44.2%	120.4cm ²	68.4%	57.6%
70代	109.4cm ²	50.4%	104.8cm ²	83.1%	49.3%
全年代	102.4cm ²	50.2%	115.6cm ²	72.1%	59.8%
40歳以上	103.9cm ²	48.8%	121.1cm ²	68.9%	61.3%

女性

内臓脂肪面積	感度80%の値	感度80%の特異度	感度+特異度が最大の値	感度	特異度
40歳未満	36.5cm ²	51.2%	60.2cm ²	70.0%	80.5%
40代	66.4cm ²	67.7%	63.3cm ²	85.0%	66.1%
50代	68.3cm ²	53.2%	67.8cm ²	82.9%	53.0%
60代	75.7cm ²	43.0%	97.7cm ²	65.9%	65.7%
70代	77.3cm ²	43.1%	75.7cm ²	87.1%	43.1%
全年代	69.0cm ²	54.0%	67.8cm ²	82.9%	53.5%
40歳以上	69.2cm ²	50.9%	97.6cm ²	60.4%	74.5%

なる内臓脂肪面積を用いた場合、40歳未満では40歳以上と比べて感度が低く(男性70.0%, 女性60.0%), 40歳未満ではより小さい内臓脂肪面積のカットオフ値を採用すべきであることが示された。先行研究においてわれわれは、内臓脂肪蓄積の簡易代替指標として用いられているウエストは、内臓脂肪面積と比べて男性では7割、女性では5割のメタボリックシンドロームのリスク重積しか捉えられないことを明らかにしており、今後は、内臓脂肪面積のより簡易な測定法を検討していく必要があるとも考えられる。

(国立国際医療研究センター臨床研究支援部 松下 由実)

(国立国際医療研究センター糖尿病・代謝症候群診療部

野田 光彦)

参考文献

1. Matsushita Y, Nakagawa T, Yamamoto S, et al : Associations of visceral and subcutaneous fat areas with the prevalence of metabolic risk factor clustering in 6,292 Japanese individuals: the Hitachi Health Study. *Diabetes Care* 33 : 2117-2119, 2010

